RMDM

What RMDM does

RMDM is a privately-held UK healthcare group (registered as RMDM Limited in England and Wales, headquartered in London) that operates across diagnostics, pharma, and nutrition with a stated focus on cancer early detection and metabolic health. The company is built around the scientific work of co-founder Dr. Johannes Coy on the TKTL1 metabolic enzyme, which underpins both the diagnostic and nutraceutical arms of the business. RMDM operates through four wholly-owned subsidiaries: RMDM Limited (group entity), RMDM Diagnostics Limited (PanTum Detect testing services), RMDM Pharma Limited, and RMDM Sugars Limited (nutraceutical sugar products).

The core technology is PanTum Detect, a liquid-biopsy blood test based on EDIM (Epitope Detection in Monocytes) that measures two biomarkers — Apo10 and TKTL1 — to identify tumour-associated antigens within monocytes, capturing the immune system's response to malignancy rather than relying on tumour DNA shedding (ctDNA) or circulating tumour cells. The company reports 97.5% sensitivity and 99.05% specificity across multiple cancer types, validated in a 5,000-participant study, and positions the test as a universal, annual, population-level screening tool deployable through primary care, occupational health, and community clinics. The proprietary RMDM® and PanTum Detect® trademarks are registered.

RMDM generates revenue through B2B test-kit/service fees to healthcare providers, hospital systems, national health authorities, and private clinics, plus consumer sales of natural nutraceutical sugars under RMDM Sugars. Its go-to-market is enterprise field sales, supplemented by channel partners (e.g., Doctors Centre Lab in Lebanon, Centre For Health and Human Performance in the UK), with government health ministries (Jordan, Abu Dhabi Department of Health) targeted for national screening programme integration. Pricing is not publicly disclosed.

Name

RMDM

Legal name

RMDM Limited

Website

https://rmdm.group

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

RMDM is a UK-based private diagnostics and metabolic-health group selling PanTum Detect, an EDIM-based liquid-biopsy blood test for multi-cancer early detection (Apo10/TKTL1 biomarkers), alongside nutraceutical sugars, to health systems, hospitals, and clinics in the UK and Middle East.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics Services

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK)

Keywords

• Cancer early detection
• Liquid biopsy diagnostics
• Multi-cancer blood test
• Nutraceutical sugar products
• Metabolic health solutions

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. PanTum Detect Diagnostic Blood Test: RMDM generates revenue through the sale of its PanTum Detect multi-cancer early detection blood test to healthcare providers, hospitals, national health systems, and private clinics. The test is positioned as a first point of information — a routine screening or diagnostic blood draw that determines whether patients require further investigation, thereby reducing downstream diagnostic costs. Revenue is derived from test-kit/service fees to institutional buyers (B2B model) and potentially individual consumers through clinic and occupational health channels.
2. Nutraceutical Sugars (RMDM Sugars): RMDM sells a range of natural sugars marketed as health-enhancing nutritional products that improve everyday well-being. These sugar-based products are sold as part of a broader 'one-stop-shop' health offering combining diagnostics, pharma, and nutrition — targeting both consumer wellness and clinical nutrition applications alongside cancer care.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels10 records

Core offering

RMDM provides PanTum Detect, a proprietary multi-cancer early detection blood test based on EDIM technology that identifies tumour-associated antigens (Apo10 and TKTL1) within monocytes, achieving 97.5% sensitivity and 99.05% specificity for early-stage cancer detection. The company also offers diagnostic services integrating blood-based biomarker analysis with follow-up imaging, alongside RMDM Sugars — natural sugar-based nutraceutical products positioned as part of an integrated diagnostics, pharma, and nutrition one-stop-shop.

Product overview

RMDM Group operates as a one-stop-shop for healthier living and disease prevention, offering a unified portfolio of diagnostics, pharma, and nutrition solutions. The core offering centers on PanTum Detect, the world's first universal cancer blood test that detects immune responses to cancer, complemented by diagnostic imaging services. The company also provides natural sugars/nutraceuticals and leverages TKTL1 technology - a metabolic enzyme approach to cancer - as the biological foundation bridging molecular research with clinical strategies.

Differentiator

Problem solved

Functional benefit

Products and services

• PanTum Detect The world's first universal cancer blood test for the early detection of all cancers, identifying tumour-associated antigens within monocytes by detecting the body's immune response to cancer. Achieves 97.5% sensitivity and 99.05% specificity across multiple cancer types and detects cancer 6–18 months before symptoms appear. Sold to healthcare providers, hospitals, NHS trusts, national health authorities, and diagnostic laboratories for use in primary care, occupational health, pharmacy networks, and community clinics.
• Diagnostics Services

Quantifiable outcome

• PanTum Detect achieves 97.5% sensitivity and 99.05% specificity in detecting cancer cells
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Doctors Centre Lab (Lebanon)coreChannel Partner/ Reseller/ DistributorDoctors Centre Lab in Lebanon served as the launch partner for PanTum Detect in the Middle East. RMDM launched PanTum Detect with Doctors Centre Lab at the InterContinental Phoenicia in Beirut, with the event attended by 150 doctors, oncologists, and medical professionals. This partnership established the first PanTum Detect testing facility in the MENA region.
• Centre For Health and Human PerformancecoreChannel Partner/ Reseller/ DistributorRMDM partnered with Centre For Health and Human Performance to provide PanTum Detect cancer blood testing services in the UK private healthcare sector. This partnership contributed to a significant increase in demand for PanTum Detect in the UK, positioning the test within a premium private health and performance clinic setting.
• Mike Farrar CBE (NHS Confederation)minorOthersRMDM Diagnostics appointed Mike Farrar CBE, former Chief Executive of the NHS Confederation, as lead adviser for its pan-cancer blood test PanTum Detect. Mike Farrar brings NHS policy and healthcare system expertise to support adoption and integration of PanTum Detect within UK health services.
• Jordan Ministry of HealthcoreStrategic or Co-development PartnerRMDM was invited by His Excellency Dr Saad Jaber, Minister of Health of Jordan, to meet with the Ministry's senior team. Early detection is high on the Jordan Ministry's agenda and Jordan is supportive of innovative technologies for cancer care. RMDM expressed intent to bring PanTum Detect to Jordan.
• UK Department of International Trade (DIT)minorGTM or Marketing PartnerThe UK Department of International Trade supported RMDM Group's international business development activities, including arranging meetings at the UK Embassy in Beirut and facilitating introductions to international partners and health ministries in the MENA region.
• PLMR (PR & Communications)minorGTM or Marketing PartnerPLMR, a PR and communications agency, helped organise RMDM's participation at the Conservative Party Conference 2019, supporting the company's government relations and awareness-raising activities.
• Intelligent Sugar GmbHcoreStrategic or Co-development PartnerIntelligent Sugar GmbH, founded by Dr. Johannes Coy (co-discoverer of the TKTL1 gene), is developing and launching a website to share the nutritional benefits of 'healthy' sugars and the harmful effects of conventional sugars. RMDM intends to collaborate with Intelligent Sugar to raise awareness around cancer and nutrition, aligning with RMDM's 'one-stop-shop' model combining diagnostics, pharma, and nutrition.
• Ahmed BourkhidaminorOthersAhmed Bourkhida contributed to the organisation of RMDM's participation at Medlab Middle East 2020, where RMDM delivered Transformation Talks at the conference and hosted an exhibition stand.
• UK Embassy in BeirutminorGTM or Marketing PartnerRMDM Group met with Her Majesty's Ambassador Christopher Rampling MBE at the UK Embassy in Beirut. The embassy engagement supported RMDM's international business development and introduction to regional health sector contacts.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• GRAIL: GRAIL develops the Galleri multi-cancer early-detection (MCED) blood test and is the most direct competitor to RMDM's PanTum Detect. Both target population-level cancer screening via a single blood draw; the recent large-scale Galleri study failure is explicitly cited by RMDM as creating an opening for biologically grounded alternatives like EDIM.
• Oncimmune: UK-based (Nottingham) blood-based cancer detection company commercializing the EarlyCDT Lung and EarlyCDT platforms. Closely comparable to RMDM on geography (UK), technology category (blood-based oncology diagnostics), and customer base (primary care / screening settings).
• VolitionRx: Multi-cancer blood-based diagnostics company using Nu.Q nucleosome-based biomarkers. Comparable to RMDM as a smaller-cap, blood-based multi-cancer detection company targeting population screening, though Volition's biomarker technology is mechanistically distinct from EDIM.
• Freenome: Freenome is a multiomics-based blood test developer focused on early cancer detection (lead program in colorectal cancer screening with expansion into MCED). Directly comparable to RMDM as a blood-based, population-screening-oriented cancer diagnostics company pursuing primary-care adoption.
• Thrive Earlier Detection: Developed a blood-based MCED test (CancerSEEK) and was acquired by Exact Sciences; frequently cited alongside Galleri as one of the leading MCED programs. Direct competitor in the multi-cancer blood test category targeting population screening.

Emerging players

• Personalis: Liquid biopsy company offering tumor-informed MRD (NeXT Personal) and immuno-oncology biomarker profiling. Comparable to RMDM in liquid biopsy / oncology biomarker category and in MRD use cases; smaller scale with overlapping customer base of oncologists and biopharma.

Broad incumbents

• Guardant Health: A leading liquid biopsy company offering oncology blood tests across screening (Shield for CRC), therapy selection (Guardant360), and MRD (Guardant Reveal). Overlaps with RMDM in liquid biopsy technology category and cancer screening use cases, but operates a much broader oncology portfolio.
• Natera: Developer of Signatera, a leading tumor-informed MRD blood test, plus women's health and organ transplant tests. Comparable to RMDM in MRD/post-surgical monitoring use cases and liquid biopsy technology category, though with substantially deeper clinical evidence and U.S. payer reimbursement.
• Exact Sciences: Commercialized Cologuard (the leading stool-based CRC screening test) and acquired Thrive Earlier Detection to enter MCED. Comparable as a cancer screening platform pursuing blood- and non-blood-based population screening, though at vastly larger scale and regulatory maturity.

Regional players

• Burning Rock Biotech: China-based liquid biopsy company offering therapy selection and MRD tests. Comparable to RMDM in technology category (NGS-based and blood-based oncology diagnostics) but operates in a distinct geographic market and emphasizes therapy selection over screening.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/rmdm_group
• LinkedInlinkedin.com/company/rmdm-group

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RMDM